2014
Denosumab for Treatment of Hypercalcemia of Malignancy
Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for Treatment of Hypercalcemia of Malignancy. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3144-3152. PMID: 24915117, PMCID: PMC4154084, DOI: 10.1210/jc.2014-1001.Peer-Reviewed Original ResearchConceptsHypercalcemia of malignancyProportion of patientsDay 10Serum calciumBone resorptionCommon serious adverse eventsMedian response durationSerious adverse eventsSerum calcium levelsTreatment of hypercalcemiaDuration of responseNew treatment optionsBisphosphonate therapyPrimary endpointSecondary endpointsAdverse eventsBisphosphonate treatmentDurable responsesComplete responseAdvanced cancerTreatment optionsHematologic malignanciesResponse durationDenosumabCalcium levels
1982
Influence of pregnancy on immunoreactive parathyroid hormone levels
Gillette M, Insogna K, Lewis A, Baran D. Influence of pregnancy on immunoreactive parathyroid hormone levels. Calcified Tissue International 1982, 34: 9-12. PMID: 6279256, DOI: 10.1007/bf02411200.Peer-Reviewed Original ResearchConceptsImmunoreactive PTHTubular maximum phosphate reabsorptionImmunoreactive parathyroid hormone levelsAge-matched female controlsHealthy pregnant patientsNephrogenous cAMP excretionParathyroid hormone metabolismHealthy age-matched female controlsParathyroid hormone levelsInfluence of pregnancySignificant increaseBiological effectsIPTH levelsPregnant patientsCreatinine clearanceUrinary calciumCreatinine ratioPTH metabolismSerum calciumSerum phosphorusThird trimesterVitamin DBlood levelsBone resorptionPhosphate reabsorption